CRBN and plasma cell myeloma: Lastly, as new targeted agents emerge (e.g. cereblon E3 ligase modulators in myeloma and chimeric antigen receptor NK-cell therapies, etc.), it will be important to systematically monitor for ocular AEs from the outset, learning from the lessons of prior therapies.